Acurx Pharmaceuticals financials
$1.31−2.61%
Close Sep 29, 2026 · split-adjustedRevenue
Net income
Income statement & cash flow
| Fiscal year | FY25 Dec 31 | FY24 Dec 31 | FY23 Dec 31 | FY22 Dec 31 | FY21 Dec 31 |
|---|---|---|---|---|---|
| Revenue | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross profit | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Gross margin | — | — | — | — | — |
| Operating income | -$8.1M | -$14.1M | -$14.6M | -$12.1M | -$12.8M |
| Net income | -$8.0M | -$14.1M | -$14.6M | -$12.1M | -$12.7M |
| Net margin | — | — | — | — | — |
| Diluted EPS | $-5.32 | $-17.45 | $-23.00 | $-22.40 | $-29.80 |
| EBITDA | -$8.1M | -$14.1M | -$14.6M | -$12.1M | -$12.8M |
| Operating cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | -$5.0M |
| Free cash flow | -$6.8M | -$10.4M | -$9.8M | -$7.5M | — |
| Diluted shares | 1.5M | 0.8M | 0.6M | 0.5M | 0.4M |
Balance sheet
| Period end | Dec 31 | Dec 31 | Dec 31 | Dec 31 | Dec 31 |
|---|---|---|---|---|---|
| Cash & equivalents | $7.6M | $3.7M | $7.5M | $9.1M | $13.0M |
| Short-term investments | $0.00 | $0.00 | $0.00 | $0.00 | — |
| Total debt | $0.00 | $0.00 | $0.00 | $0.00 | $0.00 |
| Total assets | $7.7M | $3.9M | $7.7M | $9.4M | $13.3M |
| Total liabilities | $2.4M | $3.2M | $3.0M | $2.1M | $843.9K |
| Shareholders' equity | $5.3M | $615.1K | $4.7M | $7.3M | $12.4M |
From SEC filings via Massive. Fiscal periods follow the company's own calendar; free cash flow is operating cash flow minus capital expenditure.
Sources: Massive / Polygon daily aggregates (split-adjusted) · SEC filings via Massive · FINRA settlements via Massive · Financial Modeling Prep. Figures are dated where shown; research is informational, not investment advice. Methodology